Elios Therapeutics

Elios Therapeutics is a private, clinical-stage biotech company advancing personalized cancer vaccines. Its core technology platform utilizes autologous tumor lysate to create patient-specific vaccines that aim to train the immune system to recognize and destroy residual cancer cells, potentially preventing recurrence. The company's lead program, the TLPO vaccine, has progressed to Phase IIb clinical trials in high-risk melanoma, positioning it in a competitive but high-potential segment of immuno-oncology. Elios operates from Greenville, South Carolina, and appears to be in a pre-revenue, venture-backed stage of development.

Autologous personalized cancer vaccine platform using whole tumor lysate loaded onto a particle-based delivery system to stimulate a patient-specific anti-tumor immune response.

Elios competes in the personalized cancer vaccine space with companies like BioNTech, Moderna (mRNA-based neoantigen vaccines), and Gritstone bio. It also faces indirect competition from standard-of-care adjuvant therapies like PD-1 inhibitors (Keytruda, Opdivo) in melanoma. Its whole-lysate approach differentiates it from computationally selected neoantigen vaccines.